Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-125537
Filing Date
2024-11-12
Accepted
2024-11-12 16:33:34
Documents
72
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q inab-20240930.htm   iXBRL 10-Q 1892494
2 EX-10.2 inab-ex10_2.htm EX-10.2 344507
3 EX-10.3 inab-ex10_3.htm EX-10.3 65155
4 EX-10.4 inab-ex10_4.htm EX-10.4 65494
5 EX-10.5 inab-ex10_5.htm EX-10.5 47725
6 EX-10.8 inab-ex10_8.htm EX-10.8 68450
7 EX-10.9 inab-ex10_9.htm EX-10.9 45358
8 EX-31.1 inab-ex31_1.htm EX-31.1 18438
9 EX-31.2 inab-ex31_2.htm EX-31.2 17918
10 EX-32.1 inab-ex32_1.htm EX-32.1 15440
11 GRAPHIC img239790349_0.jpg GRAPHIC 158989
  Complete submission text file 0000950170-24-125537.txt   7851244

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT inab-20240930.xsd EX-101.SCH 1002166
74 EXTRACTED XBRL INSTANCE DOCUMENT inab-20240930_htm.xml XML 950758
Mailing Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118
Business Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118 (646) 600-6438
IN8BIO, INC. (Filer) CIK: 0001740279 (see all company filings)

EIN.: 825462585 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39692 | Film No.: 241449032
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)